Johnson & Johnson to Launch Late-Stage Coronavirus Vaccine Trials in September
Might Johnson & Johnson (NYSE: JNJ) soon vault to the top of the coronavirus stock list?
It's conceivable, as an entry on the government's list of clinical trials reveals that the company's Janssen Vaccines subsidiary is about to launch a relatively large-scale, phase 3 study of its Ad26.COV2-S vaccine candidate. The estimated start date is Sept. 5, with both the primary and completion date anticipated for March 10, 2023.
All told, the Johnson & Johnson/Janssen study aims to involve roughly 60,000 participants with moderate to severe COVID-19, age 18 and older. It will be a randomized, double-blind, and placebo-controlled trial.
Source Fool.com
